Creative Biolabs provides a specialized analytical ecosystem to validate myeloid-targeting therapeutics, including antibodies, small molecules, and CAR-M. We quantify a candidate’s ability to disrupt the tumor-associated macrophages (TAMs)-mediated "molecular shield" using standardized phagocytic index (PI) measurements and phenotypic switching assays. Whether targeting the SIRP-α/CD47 axis or LILRB receptors, our platform delivers actionable, high-resolution data to identify leads with the highest probability of success, transitioning candidates from simple binders to potent functional modulators.

Macrophage Checkpoint Biology

The immunosuppressive landscape of the tumor microenvironment (TME) is critically governed by TAMs, which often constitute the majority of the infiltrating immune population. Recent scientific literature establishes that TAMs facilitate tumor escape by expressing a distinct repertoire of co-inhibitory receptors, which act as "checkpoints" to paralyze the innate immune response and block phagocytosis. These myeloid-specific inhibitors create a physical and chemical "molecular shield" that renders traditional T-cell therapies ineffective. Creative Biolabs leverages these insights to provide a high-throughput evaluation platform that measures a lead candidate’s ability to disrupt these shields, restore phagocytic activity, and promote pro-inflammatory M1-like anti-tumor immunity.

Strategic Evaluation Offerings

Creative Biolabs provides an expansive suite of evaluation targets that represent the cutting edge of myeloid biology. Our offerings go beyond standard markers to include:

Unlock the Potential of Your Myeloid Leads — Consult with Our Experts Today

Workflow

Our process is engineered for scientific rigor and industrial transparency, moving your project from initial material submission to a definitive lead-ranking matrix.

Publication

This review focuses on immune checkpoints expressed on TAMs and their roles in cancer immunotherapy. It examines key checkpoints, including PD-1/PD-L1, CD47/SIRP-α, CD39/CD73, VISTA, and Siglec-10, discussing how they regulate macrophage phagocytosis, polarization, and immunosuppression. The authors summarize regulatory mechanisms and highlight combination strategies, such as CSF1R inhibitors, nanoparticles, and bispecific antibodies, to enhance immune checkpoint blockade efficacy. Targeting TAM checkpoints represents a promising avenue to overcome resistance and improve antitumor immunity.

Fig.1 The landscape of immune checkpoints in macrophages. ¹

Why Choose Us?

Creative Biolabs stands at the global forefront of myeloid-centric drug discovery, offering a unique combination of legacy antibody engineering and analytical technologies. Unlike generic CROs that focus solely on T-cell responses, we prioritize cell-type specificity to help you minimize immune-related adverse events (irAEs) by focusing the immune response on the tumor-resident myeloid compartment. Our platform utilizes high-resolution spatial multi-omics and published data to benchmark all assays, ensuring your lead candidates are validated against industry standards. By choosing Creative Biolabs, you gain access to proprietary polarization protocols and sophisticated humanized myeloid models that provide a multi-dimensional view of efficacy.

Experience the Creative Biolabs Advantage - Request a Custom Quote

FAQs

Q1: Can you evaluate bispecific antibodies targeting both T-cells and macrophages?

A1: Absolutely. Our 3D co-culture models are specifically designed to measure the synergistic effects of multi-specific biologics on both innate and adaptive compartments.

Q2: How do you ensure the macrophages represent actual TAMs?

A2: We use proprietary cytokine cocktails and tumor-conditioned media to induce a stable, M2-like phenotype that mimics the clinical TME.

Q3: Do you offer screening for novel checkpoints like LILRB4 or Siglec-10?

A3: Yes, we have validated protocols for the full range of emerging myeloid checkpoints, including metabolic enzymes like CD39 and CD73.

Customer Review

• Accelerated Myeloid Insight Generation
  Using Creative Biolabs' evaluation services in our research has significantly improved the ranking of our CD47-targeting leads. The clear phagocytic index data correlated perfectly with our in vivo results. - Dr. A***n L
• Superior Metabolic & Phenotypic Resolution
  The depth of knowledge regarding the lipid metabolism-immune axis was impressive. Their report helped us understand the metabolic shift our drug induced in TAMs, which was critical for our board presentation. - Mark R***l

Related Services

To further your research, Creative Biolabs offers:

How to Contact Creative Biolabs

Creative Biolabs offers an industry-leading macrophage immune checkpoint evaluation platform that integrates high-resolution science with commercial efficiency. From validating "Don't Eat Me" signals to exploring the LILRB and metabolic frontiers, we provide the data you need to secure your lead in the myeloid revolution.

Partner with Creative Biolabs to Redefine Your Oncology Pipeline — Discuss Your Project with Us Today

Reference

1. Xu, Shumin, et al. "Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy." Frontiers in Immunology 14 (2023): 1199631. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2023.1199631